{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:12:52Z","timestamp":1781140372550,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T00:00:00Z","timestamp":1615852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T00:00:00Z","timestamp":1615852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002954","name":"Universit\u00e0 degli Studi di Milano - Bicocca","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002954","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s40261-021-01023-8","type":"journal-article","created":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T16:02:59Z","timestamp":1615910579000},"page":"459-468","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0349-3221","authenticated-orcid":false,"given":"Pietro","family":"Ferrara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo A.","family":"Cortesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Di Laura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo P.","family":"Maggioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo G.","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,16]]},"reference":[{"key":"1023_CR1","doi-asserted-by":"crossref","unstructured":"GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204\u201322.","DOI":"10.1016\/S0140-6736(20)30925-9"},{"issue":"25","key":"1023_CR2","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990 to 2019: update from the global burden of disease 2019 study. J Am Coll Cardiol. 2020;76(25):2982\u20133021. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.010.","journal-title":"J Am Coll Cardiol"},{"key":"1023_CR3","doi-asserted-by":"crossref","unstructured":"Antithrombotic Trialists\u2019 (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849\u201360.","DOI":"10.1016\/S0140-6736(09)60503-1"},{"key":"1023_CR4","doi-asserted-by":"crossref","unstructured":"The EINSTEIN\u2013PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287\u201397.","DOI":"10.1056\/NEJMoa1113572"},{"key":"1023_CR5","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"The EINSTEIN Investigators","year":"2010","unstructured":"The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499\u2013510.","journal-title":"N Engl J Med"},{"key":"1023_CR6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u201391.","journal-title":"N Engl J Med"},{"issue":"14","key":"1023_CR7","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","volume":"377","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319\u201330.","journal-title":"N Engl J Med"},{"key":"1023_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5058","volume":"359","author":"JA Lopez-Lopez","year":"2017","unstructured":"Lopez-Lopez JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;359:","journal-title":"BMJ"},{"issue":"9","key":"1023_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21090","volume":"21","author":"JA Sterne","year":"2017","unstructured":"Sterne JA, Bodalia PN, Bryden PA, et al. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess. 2017;21(9):1\u2013386.","journal-title":"Health Technol Assess"},{"issue":"11","key":"1023_CR10","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1093\/cvr\/cvz278","volume":"116","author":"MR Cowie","year":"2020","unstructured":"Cowie MR, Lamy A, Levy P, Mealing S, Millier A, Mernagh P, Cristeau O, Bowrin K, Briere JB. Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease. Cardiovasc Res. 2020;116(11):1918\u201324.","journal-title":"Cardiovasc Res"},{"issue":"13","key":"1023_CR11","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1177\/2047487320913380","volume":"27","author":"S Petersohn","year":"2020","unstructured":"Petersohn S, Pouwels X, Ramaekers B, Ten Cate-Hoek A, Joore M. Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study. Eur J Prev Cardiol. 2020;27(13):1354\u201365.","journal-title":"Eur J Prev Cardiol."},{"key":"1023_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ijcard.2018.06.091","volume":"270","author":"Z Ademi","year":"2018","unstructured":"Ademi Z, Zomer E, Tonkin A, Liew D. Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: an Australian perspective. Int J Cardiol. 2018;270:54\u20139.","journal-title":"Int J Cardiol"},{"issue":"8","key":"1023_CR13","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1177\/2047487318817910","volume":"26","author":"E Zomer","year":"2019","unstructured":"Zomer E, Si S, Hird TR, et al. Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: an Australian healthcare perspective. Eur J Prev Cardiol. 2019;26(8):858\u201368.","journal-title":"Eur J Prev Cardiol."},{"key":"1023_CR14","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). Common Drug Review\u2014Pharmacoeconomic Review Report for Rivaroxaban (Xarelto). CADTH; 2019."},{"issue":"5","key":"1023_CR15","first-page":"1","volume":"18","author":"D Panteli","year":"2016","unstructured":"Panteli D, Arickx F, Cleemput I, et al. Pharmaceutical regulation in 15 European countries: review. Health Syst Trans. 2016;18(5):1\u2013118.","journal-title":"Health Syst Trans"},{"key":"1023_CR16","unstructured":"Istituto nazionale di statistica (ISTAT). I.Stat database. http:\/\/dati.istat.it. Accessed 9 Feb 2021."},{"key":"1023_CR17","unstructured":"Italian Diagnosis-Related Group (DRG). Decreto del Ministero della Salute 18 ottobre 2012. In: Gazzetta Ufficiale della Repubblica Italiana n. 23 del 28 gennaio 2013."},{"issue":"1","key":"1023_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ijcard.2011.04.030","volume":"150","author":"LG Mantovani","year":"2011","unstructured":"Mantovani LG, Fornari C, Madotto F, et al. Burden of acute myocardial infarction. Int J Cardiol. 2011;150(1):111\u20132.","journal-title":"Int J Cardiol"},{"issue":"3","key":"1023_CR19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1159\/000475842","volume":"10","author":"M Lucchese","year":"2017","unstructured":"Lucchese M, Borisenko O, Mantovani LG, et al. Cost-utility analysis of bariatric surgery in italy: results of decision-analytic modelling. Obes Facts. 2017;10(3):261\u201372.","journal-title":"Obes Facts."},{"issue":"4","key":"1023_CR20","first-page":"572","volume":"59","author":"EM Marone","year":"2018","unstructured":"Marone EM, Cozzolino P, Ciampichini R, et al. Peripheral arterial disease in diabetic patients: a long-term population-based study on occurrence, outcomes and cost. J Cardiovasc Surg (Torino). 2018;59(4):572\u20139.","journal-title":"J Cardiovasc Surg (Torino)."},{"key":"1023_CR21","unstructured":"Agenzia italiana del farmaco (AIFA). Liste di trasparenza e rimborsabilit\u00e0. http:\/\/www.agenziafarmaco.gov.it\/content\/liste-di-trasparenza-e-rimborsabilita. Accessed 9 Feb 2021."},{"key":"1023_CR22","unstructured":"Agenzia italiana del farmaco (AIFA). Determina del 27 settembre 2006\u2014Manovra per il governo della spesa farmaceutica convenzionata e non convenzionata. https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2006-09-29&atto.codiceRedazionale=06A08826&elenco30giorni=false. Accessed 9 Feb 2021."},{"key":"1023_CR23","doi-asserted-by":"crossref","unstructured":"Cortesi PA, Belli LS Facchetti R, et al. The optimal timing of hepatitis C therapy in liver transplant-eligible patients: cost-effectiveness analysis of new opportunities. J Viral Hepat. 2018;25(7):791\u2013801.","DOI":"10.1111\/jvh.12877"},{"key":"1023_CR24","first-page":"2016","volume-title":"Microsoft Office Professional Plus 2016","author":"Microsoft Excel\u00ae (Software).","year":"2016","unstructured":"Microsoft Excel\u00ae (Software). Microsoft Office Professional Plus 2016. Redmond: Microsoft Corporation; 2016. p. 2016."},{"issue":"23","key":"1023_CR25","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1161\/CIRCULATIONAHA.120.046448","volume":"141","author":"DL Bhatt","year":"2020","unstructured":"Bhatt DL, Eikelboom JW, Connolly SJ, et al. The role of combination antiplatelet and anticoagulation therapy in diabetes and cardiovascular disease: insights from the COMPASS trial. Circulation. 2020;141(23):1841\u201354. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.046448.","journal-title":"Circulation"},{"key":"1023_CR26","volume-title":"Economic evaluation in clinical trials","author":"HA Glick","year":"2015","unstructured":"Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation in clinical trials. Oxford: Oxford University Press; 2015."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01023-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-021-01023-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01023-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T07:13:41Z","timestamp":1621926821000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-021-01023-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,16]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1023"],"URL":"https:\/\/doi.org\/10.1007\/s40261-021-01023-8","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,16]]},"assertion":[{"value":"6 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi di Milano - Bicocca within the CRUI-CARE Agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Pietro Ferrara, Paolo A. Cortesi, Danilo Di Laura, Aldo P. Maggioni, and Lorenzo G. Mantovani have no\u00a0conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study did not involve participants as information was gathered from previously published research and freely accessible public databases; thus, no ethical approval was required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the conception or design of the work and the acquisition, analysis and interpretation of data, and drafted and critically revised the manuscript. All authors gave final approval and agree to be accountable for all aspects of the work, ensuring integrity and accuracy.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}